PRINCETON, N.J., Aug. 5 /PRNewswire/ -- Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer. Dr. Shroot replaces Dr. Gregory Stock who will continue to remain active with the Company as a member of the board.
"Braham Shroot brings to Signum an outstanding track record of success in growing value at both start-up and major pharmaceutical companies including Barrier Therapeutics, DFB Bioscience, and Galderma," said Maxwell Stock, President of Signum Biosciences. "We welcome him to the Signum team and look forward to seeing the company progress under his leadership."
"This is a very exciting time for Signum, with the commercialization of the company's first skin-care compound, Arazine™, by its partner, Rohto Pharmaceutical in Japan," said Dr. Shroot. "I am equally enthusiastic about Signum's innovative pipeline which holds significant potential to help patients with difficult-to-treat chronic inflammatory and age related pathologies."
Braham Shroot Biography
Braham Shroot is the former CSO of Barrier Therapeutics, Inc., a public dermatology-focused pharmaceutical company, which was acquired by Stiefel Laboratories Inc., in August 2008. Prior to Barrier, Dr. Shroot was CSO and Vice President of R&D for DFB Pharmaceuticals, Inc., a fully integrated private specialty pharmaceutical company with a focus on skin, wound care, and surgical markets. Before DFB, Dr. Shroot was at L'Oreal where he was G
|SOURCE Signum Biosciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved